In November, daratumumab won regulatory approval for a cancer that doesn't officially exist yet—not because the science is new, but because medicine is finally learning to think ahead. The drug targets smoldering myeloma, a premalignant state that sits quietly in patients' bodies before transforming into the fatal form of multiple myeloma. It took 15 years from initial research to this milestone, but the logic behind it is reshaping how the entire field approaches cancer in 2026: why wait to treat a disease after it emerges when you can intercept it before it becomes life-threatening?
This shift represents a fundamental reorientation in oncology. For decades, cancer research has focused on treating established disease—tumors already diagnosed and advancing. But leading cancer researchers gathered by the American Association for Cancer Research now speak of moving "upstream," toward prevention, early detection, and what they call interception: treating premalignant conditions before they ever become cancer. William Hait, AACR Chief Scientific Advisor and a medical oncologist who spent 30 years treating cancer patients, frames the challenge in patient terms. His clinic patients would ask him: "I didn't smoke, I didn't drink, no one in my family has cancer. What could I have done to prevent this?" The answer, increasingly, is intervening long before a diagnosis arrives.
The interception strategy is already expanding beyond myeloma. Ductal carcinoma in situ of the breast—essentially cancer cells confined within milk ducts—has been treated preventatively for years. Now similar logic is expected to reach other high-risk precancerous conditions: Barrett esophagus, which elevates esophageal cancer risk; prostate intraepithelial neoplasia, linked to prostate cancer; and clonal hematopoiesis of indeterminate potential, or CHIP, which increases blood cancer risk. The framework is straightforward but profound: identify measurable biological transitions long before overt cancer occurs and treat those transitions as a means of reducing risk.
Parallel advances are sharpening early detection for established screening programs. Lung cancer screening using low-dose CT scans has saved lives but struggled with a persistent problem—too many false alarms. Radiomics, the application of artificial intelligence to extract quantitative features from clinical images, is now helping doctors distinguish which pulmonary nodules truly warrant concern, reducing unnecessary procedures and anxiety. Similarly, blood-based tests, or liquid biopsies, are improving as researchers generate more data and apply machine learning to distinguish genuine cancer signals from noise.
The convergence of these advances—interception, precision imaging, liquid biopsies, and AI—signals that 2026 will not be defined by a single breakthrough but by a philosophical shift in timing. Rather than asking "How do we treat this cancer?" the field is asking "How do we prevent it from ever becoming cancer?" This requires closing gaps in care and access, reducing health disparities, and ensuring that prevention strategies don't further divide those with resources from those without. But the scientific foundation is solid. After 15 years of patience, daratumumab's November approval proves the payoff is real.